A 2024 narrative review in Current Pain and Headache Reports finds that the endocannabinoid system offers a biologically compelling target for acute pain management, but clinical trials to date have been too small, inconsistent, and poorly standardized to confirm that cannabinoids reliably work. The gap between laboratory promise and bedside proof remains the defining challenge for this therapeutic class.

Cannabinoid use among patients experiencing acute and perioperative pain has surged well beyond the pace of clinical evidence or regulatory guidance. Clinicians are confronted daily with patients who self-administer cannabis products before and after surgery, often without disclosing this use, and who may assume therapeutic benefit that has not been rigorously demonstrated. The opioid crisis has intensified interest in non-opioid alternatives, but urgency must not be confused with evidence. Understanding precisely where the science stands on cannabinoids for acute pain is now an essential clinical competency.

The endocannabinoid system, comprising CB1 and CB2 receptors and their endogenous ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG), is distributed throughout peripheral nociceptors, spinal dorsal horn neurons, and supraspinal structures including the periaqueductal gray and rostral ventromedial medulla. This anatomical positioning provides a credible biological basis for cannabinoid modulation of pain at every level of the nociceptive pathway. The review explores how CB1 activation in the central nervous system mediates the primary analgesic and psychoactive effects of THC, while CB2 receptors, which are upregulated during tissue injury and inflammation, may offer a potentially safer immunomodulatory target with reduced psychoactive burden. Additional receptors such as TRPV1, GPR55, and PPARs add further pharmacological complexity.

Despite this mechanistic richness, the clinical evidence synthesized in this review does not support definitive conclusions about cannabinoid efficacy for acute pain. The authors report that existing trials have produced inconsistent results, with many studies limited by small sample sizes, retrospective designs, poor dosing standardization, and the inability to adequately control for placebo and expectancy effects. Cannabis product variability further complicates interpretation, as phytocannabinoid content differs substantially across preparations. The review explicitly concludes that large, rigorously designed randomized controlled trials using standardized cannabinoid formulations across diverse clinical pain populations are needed before evidence-based recommendations can be made. The 2022 ASRA practice guideline on perioperative cannabis management is cited as the most actionable resource available to clinicians in the interim.

I appreciate the honesty of this review. The authors do not oversell their findings, and the mechanistic pharmacology is genuinely well-presented. This is the kind of paper I wish more patients would read before concluding that cannabis is a proven painkiller, because the biology is real and fascinating, but the clinical proof simply is not there yet. The gap between what cannabinoids do in a petri dish or a rodent model and what they reliably do in a human experiencing postoperative pain remains stubbornly wide, and this review does not resolve it.

In my own practice, I approach cannabinoid conversations with patients proactively, especially perioperatively. I screen for use, I counsel on the uncertainty of benefits for acute pain specifically, and I discuss potential interactions with anesthetic agents. I lean on the ASRA 2022 guideline as a framework. What I do not do is recommend cannabinoids as a substitute for well-studied analgesic protocols for acute pain. When patients want to try cannabinoids for chronic conditions, that is a different and more nuanced conversation, but for acute surgical or injury-related pain, the evidence base does not yet justify clinical confidence.

This review sits at an early stage in the research arc for cannabinoids in acute pain. The mechanistic foundation it describes is well-established and unlikely to be overturned, but the translational journey from receptor pharmacology to clinical efficacy has historically been treacherous for cannabinoid therapeutics. Many drugs with strong preclinical analgesia data have failed to demonstrate meaningful benefit in adequately powered human trials. Clinicians should regard this review as a useful biological primer rather than as a basis for changing prescribing behavior. The authors’ own conclusion that clinical results are inconsistent is perhaps the most important data point in the paper.

From a pharmacological and safety standpoint, the perioperative context raises specific concerns. THC can interact with anesthetic agents, and chronic cannabis users may exhibit altered anesthetic requirements and increased postoperative pain sensitivity. CBD’s inhibition of cytochrome P450 enzymes introduces potential drug-drug interactions with commonly used perioperative medications. The variability in commercial cannabis products means that even patients reporting the same “dose” may be consuming very different pharmacological profiles. The single most actionable recommendation for clinicians reading this review is to adopt the 2022 ASRA perioperative cannabis guideline as a screening and management framework for all surgical patients, proactively asking about cannabinoid use and documenting it as part of standard preoperative assessment.

This is a narrative review, which occupies a lower tier in the evidence hierarchy than systematic reviews, meta-analyses, or original randomized controlled trials. Narrative reviews synthesize literature selectively based on the authors’ judgment rather than following a pre-registered, reproducible search protocol with defined inclusion and exclusion criteria. The single most important inference constraint is that the literature cited may not represent the full body of available evidence, meaning conclusions could shift if studies omitted from the review reported different findings. Readers should treat the mechanistic pharmacology as well-supported but regard the clinical conclusions as preliminary and subject to the authors’ selection of source material.

The review’s central conclusion, that mechanistic rationale for cannabinoid analgesia substantially outpaces clinical evidence, is consistent with the broader research landscape. The 2018 Cochrane review by Mucke and colleagues on cannabis-based medicines for chronic neuropathic pain found only modest benefit with significant adverse effects, and that review examined a chronic pain population where evidence is generally stronger than for acute pain. Aviram and Samuelly-Leichtag’s 2017 systematic review similarly concluded that evidence quality for cannabinoid analgesia was weak even in chronic pain settings. The 2022 ASRA practice guideline on perioperative cannabis, which this review directly endorses, represents the most concrete clinical decision-support tool currently available and was developed precisely because patient use had outpaced evidence.

This review neither contradicts nor meaningfully extends the prior literature. Its contribution is primarily educational, providing a pharmacological primer that contextualizes why the clinical evidence gap is so frustrating, given the apparent biological promise, and why resolving that gap requires purpose-built acute pain trials rather than extrapolation from chronic pain data.

The most likely overinterpretation of this review is concluding that cannabinoids are proven effective for acute pain. The authors themselves explicitly state that clinical results are inconsistent and that large randomized controlled trials are lacking. The richness of the mechanistic discussion may inadvertently lead readers to mistake biological plausibility for clinical proof, a logical error that is especially tempting when framed against the backdrop of the opioid crisis. Robust preclinical cannabinoid effects have historically failed to replicate consistently in adequately powered human trials, a pattern this review acknowledges without resolving.

Readers should also avoid conflating THC and CBD as interchangeable agents. The review carefully distinguishes their receptor profiles and mechanisms, and clinical implications differ substantially between these compounds. Finally, the review’s citation of a projected $100 billion cannabinoid market by 2030 reflects commercial and regulatory trends, not therapeutic validation, and should not be read as evidence of efficacy.

This narrative review contributes a clear, pharmacologically grounded explanation of why the endocannabinoid system is a biologically credible target for pain modulation. It does not establish that cannabinoids are clinically effective for acute pain, nor does it provide effect sizes, dosing guidance, or safety data sufficient to change practice. For clinicians, its most immediate practical value lies in reinforcing the need for proactive perioperative cannabinoid screening and directing practitioners to the 2022 ASRA guideline as the best currently available decision-support framework.

Does this review prove that cannabis works for acute pain?

No. The review finds that the biological mechanisms supporting cannabinoid analgesia are credible, but the clinical trials conducted so far have been too small, inconsistent, and poorly designed to confirm that cannabinoids reliably reduce acute pain in humans. The authors explicitly call for large, rigorous randomized controlled trials before any clinical recommendations can be made.

Should I use cannabis instead of opioids after surgery?

There is not enough evidence to recommend cannabinoids as a replacement for established postoperative pain medications. While the idea of opioid-sparing alternatives is appealing, switching to cannabinoids based on current evidence would mean trading a proven, if imperfect, therapy for one whose acute pain benefits have not been reliably demonstrated. Always discuss pain management options with your surgical team.

Are THC and CBD the same thing when it comes to pain relief?

No. THC and CBD have different receptor profiles and mechanisms of action. THC primarily acts on CB1 receptors in the brain and produces both analgesic and psychoactive effects, while CBD interacts with a broader range of targets including TRPV1, serotonin receptors, and PPARs, generally without producing intoxication. Their clinical effects, side effects, and drug interaction profiles are distinct, and they should not be treated as interchangeable.

Should I tell my doctor if I use cannabis before surgery?

Absolutely. Cannabis use can affect anesthetic requirements, interact with perioperative medications, and influence postoperative pain management. The 2022 ASRA guideline recommends preoperative screening for cannabis use specifically because undisclosed use can complicate surgical care. Being transparent with your healthcare team allows them to adjust your care plan appropriately.

If the biology is so strong, why hasn’t it been proven in clinical trials yet?

Many drugs that show powerful effects in laboratory and animal studies fail to produce consistent results in human clinical trials. For cannabinoids, specific challenges include the difficulty of blinding cannabis trials (patients often know if they received THC), wide variability in cannabis product composition, lack of standardized dosing, and the complexity of human pain which involves psychological and social factors that animal models cannot replicate. These hurdles do not mean cannabinoids will never prove effective, but they explain the current evidence gap.

Have thoughts on this? Share it: